Valuation: enGene Therapeutics Inc.

Market Cap 129M 113M 104M 96.15M 183M 12.21B 185M 1.24B 484M 6.02B 483M 472M 20.82B P/E 2026 *
-1.1x
P/E 2027 * -1.26x
Enterprise Value -72.62M -63.55M -58.57M -54.28M -103M -6.89B -105M -702M -273M -3.4B -273M -267M -11.76B EV / Sales 2026 *
-
EV / Sales 2027 * 0.18x
Free-Float
99.91%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: enGene Therapeutics Inc.

1 day+0.52%
1 week+10.98%
Current month+10.98%
1 month+17.07%
3 months-73.81%
6 months-77.41%
Current year-78.74%
1 week 1.76
Extreme 1.755
1.96
1 month 1.57
Extreme 1.57
1.96
Current year 1.4
Extreme 1.4
12.25
1 year 1.4
Extreme 1.4
12.25
3 years 1.4
Extreme 1.4
47.17
5 years 1.4
Extreme 1.4
47.17
10 years 1.4
Extreme 1.4
47.17
Manager TitleAgeSince
Chief Executive Officer 63 21/07/2024
Chief Tech/Sci/R&D Officer 55 23/04/2023
Director of Finance/CFO 52 26/11/2023
Director TitleAgeSince
Director/Board Member 57 07/08/2023
Chairman 68 14/05/2024
Director/Board Member 66 17/12/2023
Date Insider Type Main position Quantity % Market Cap.
06-15Free

Director

31,000 0.0463%
06-15Option

Director

31,000 0.0463%
06-15Option

Chief Technology Officer

31,000 0.0463%
Change 5-day change 1-year change 3-year change Capi.($)
+0.52%+10.98%-49.61%-82.16% 129M
-0.57%+1.76%+74.01%+129.69% 57.72B
-3.80%-6.24%+67.04%+86.36% 52.65B
+1.17%+5.83%+16.39%+468.18% 24.46B
+0.38%+1.33%-14.32%-11.76% 23.84B
-3.05%+3.06%+42.36%-5.66% 19.28B
-0.76%+4.87%+43.92%-26.78% 17.8B
+3.46%+17.72%+206.66%+364.07% 17.29B
-6.73%+9.90%+36.04% - 15.28B
+2.79%+4.91%+29.26%+195.60% 14.35B
Average -0.65%+5.74%+45.18%+124.17% 24.28B
Weighted average by Cap. -1.11%+2.59%+57.65%+139.36%

Financials

2026 *2027 *
Net sales - 6.17M 5.4M 4.98M 4.61M 8.76M 586M 8.9M 59.67M 23.21M 289M 23.17M 22.66M 999M
Net income -119M -104M -95.74M -88.74M -168M -11.27B -171M -1.15B -446M -5.56B -446M -436M -19.22B -119M -104M -95.86M -88.85M -169M -11.28B -171M -1.15B -447M -5.57B -446M -437M -19.24B
Net Debt -201M -176M -162M -150M -286M -19.1B -290M -1.95B -757M -9.43B -756M -739M -32.58B -127M -112M -103M -95.29M -181M -12.1B -184M -1.23B -479M -5.97B -479M -468M -20.64B
Logo enGene Therapeutics Inc.
enGene Therapeutics Inc., formerly enGene Holdings Inc., is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).
Employees
82
Date Price Change Volume
07/07/26 US$1.920 +0.52% 1,409,129
06/07/26 US$1.910 +7.30% 2,866,895
02/07/26 US$1.780 +1.14% 588,354
01/07/26 US$1.760 +1.73% 605,237
30/06/26 US$1.730 -2.81% 1,109,061
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
1.920USD
Average target price
3.286USD
Spread / Average Target
+71.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ENGN Stock